Leeco AM 75mg/5mg/10mg Tablet SR is a combination medication formulated to provide symptomatic relief in respiratory conditions characterized by cough, allergic rhinitis, and bronchial asthma. Each sustained-release tablet contains Ambroxol 75mg, Levocetirizine 5mg, and Montelukast 10mg. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency and easing expectoration. Levocetirizine, a second-generation antihistamine, selectively inhibits peripheral H1 receptors, effectively reducing allergic symptoms such as sneezing, nasal congestion, and rhinorrhea without causing significant sedation. Montelukast, a leukotriene receptor antagonist, blocks leukotriene D4 at the cysteinyl leukotriene receptor, thereby mitigating bronchoconstriction, inflammation, and edema associated with asthma and allergic rhinitis. The sustained-release formulation ensures prolonged therapeutic effect, enhancing patient compliance by reducing dosing frequency. Leeco AM is indicated for the management of chronic bronchitis, allergic rhinitis, and asthma where mucolytic, antihistaminic, and anti-inflammatory actions are required concurrently. It should be used under medical supervision, considering potential contraindications and drug interactions. Adverse effects may include gastrointestinal disturbances, headache, and mild sedation. Patient monitoring is advised to optimize therapeutic outcomes and minimize risks.